Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Paclitaxel

Ayoola O. Awosika  1 , Maela C. Farrar, Tibb F. Jacobs  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Paclitaxel

Ayoola O. Awosika et al.
Free Books & Documents

Excerpt

The field of oncology is in a constant state of evolution and is driven by ongoing research discoveries and advancements in treatment approaches. Paclitaxel belongs to the category of chemotherapeutic agents and is utilized as a treatment for various types of cancer. Indications for using paclitaxel encompass a range of cancers, including breast, ovarian, bladder, lung, prostate, melanoma, esophageal, Kaposi sarcoma, and various other solid tumors. This therapeutic review provides an overview of paclitaxel's indications, mechanisms of action at the cellular level, role in inhibiting cancer cell growth, essential information on dosing regimens, infusion protocols, methods of administration, and contraindications, as well as the importance of monitoring patients undergoing paclitaxel therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Ayoola Awosika declares no relevant financial relationships with ineligible companies.

Disclosure: Maela Farrar declares no relevant financial relationships with ineligible companies.

Disclosure: Tibb Jacobs declares no relevant financial relationships with ineligible companies.

References

    1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-13-S2-16. - PubMed
    1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05;354(1):34-43. - PubMed
    1. Nardi M, Aloe A, De Marco S, Cognetti F, Iacovelli A, Atlante G, Calabresi F. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol. 1997 Jun;20(3):230-2. - PubMed
    1. Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol. 1997 Jan;64(1):109-13. - PubMed
    1. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20;28(18):2958-65. - PubMed

Publication types

LinkOut - more resources